$PLX
Protalix BioTherapeutics, Inc.

2019 Q2 Form 10-Q Financial Statement

#000114420419023895 Filed on May 06, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q4
Revenue $12.25M $10.44M $10.35M
YoY Change 510.52% 129.3% 140.14%
Cost Of Revenue $2.695M $2.045M $2.280M
YoY Change 23.45% -30.06% 47.1%
Gross Profit $9.552M $8.390M $8.080M
YoY Change -5496.61% 415.04% 193.82%
Gross Profit Margin 77.99% 80.36% 78.07%
Selling, General & Admin $2.068M $2.230M $2.170M
YoY Change -4.17% -10.73% -35.03%
% of Gross Profit 21.65% 26.58% 26.86%
Research & Development $13.32M $11.70M $9.970M
YoY Change 78.21% 60.6% 1.94%
% of Gross Profit 139.48% 139.46% 123.39%
Depreciation & Amortization $370.0K $405.0K $410.0K
YoY Change -11.9% -5.81% -8.89%
% of Gross Profit 3.87% 4.83% 5.07%
Operating Expenses $15.39M $13.93M $11.75M
YoY Change 59.76% 42.39% -4.7%
Operating Profit -$5.839M -$5.534M -$3.670M
YoY Change -39.02% 7.44% -61.69%
Interest Expense -$1.900M -$1.730M -$1.760M
YoY Change 10.47% -17.22% -26.67%
% of Operating Profit
Other Income/Expense, Net -$1.904M -$1.730M
YoY Change 10.83% -17.15%
Pretax Income -$7.740M -$7.260M -$5.430M
YoY Change -8.51% 0.28% -59.2%
Income Tax
% Of Pretax Income
Net Earnings -$7.743M -$7.264M -$5.430M
YoY Change -31.44% 0.35% -59.2%
Net Earnings / Revenue -63.22% -69.58% -52.46%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.52 -$0.49 -$0.37
COMMON SHARES
Basic Shares Outstanding 148.4M 148.4M 148.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.10M $30.40M $37.80M
YoY Change -11.31% -26.39% -26.17%
Cash & Equivalents $25.10M $30.36M $37.81M
Short-Term Investments
Other Short-Term Assets $2.200M $1.706M $1.877M
YoY Change -11.96% -34.38% -2.95%
Inventory $7.000M $6.707M $8.569M
Prepaid Expenses $453.0K
Receivables $7.300M $8.565M $4.729M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $41.60M $47.34M $52.98M
YoY Change -3.37% -14.99% -15.43%
LONG-TERM ASSETS
Property, Plant & Equipment $11.80M $6.058M $6.390M
YoY Change 70.03% -17.14% -16.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.900M $1.800M $1.800M
YoY Change 11.76% 0.0% -5.26%
Total Long-Term Assets $13.60M $13.70M $8.148M
YoY Change 56.88% 50.43% -14.8%
TOTAL ASSETS
Total Short-Term Assets $41.60M $47.34M $52.98M
Total Long-Term Assets $13.60M $13.70M $8.148M
Total Assets $55.20M $61.04M $61.13M
YoY Change 6.73% -5.79% -15.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.700M $5.900M $10.27M
YoY Change 11.67% 20.41% 10.35%
Accrued Expenses $1.200M $1.300M $6.368M
YoY Change 32.61%
Deferred Revenue $9.429M $9.868M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.00M $27.04M $25.35M
YoY Change 72.51% 25.75% 11.43%
LONG-TERM LIABILITIES
Long-Term Debt $54.70M $54.00M $53.30M
YoY Change 5.19% 5.26% 3.9%
Other Long-Term Liabilities $42.00M $5.290M $5.292M
YoY Change 698.78% 2.28% 4.77%
Total Long-Term Liabilities $96.70M $93.86M $88.66M
YoY Change 12.15% 13.45% 12.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.00M $27.04M $25.35M
Total Long-Term Liabilities $96.70M $93.86M $88.66M
Total Liabilities $122.7M $120.9M $114.0M
YoY Change 21.13% 15.99% 12.14%
SHAREHOLDERS EQUITY
Retained Earnings -$322.6M
YoY Change 8.94%
Common Stock $269.7M
YoY Change 1.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$67.49M -$59.86M -$52.88M
YoY Change
Total Liabilities & Shareholders Equity $55.20M $61.04M $61.13M
YoY Change 6.73% -5.79% -15.35%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$7.743M -$7.264M -$5.430M
YoY Change -31.44% 0.35% -59.2%
Depreciation, Depletion And Amortization $370.0K $405.0K $410.0K
YoY Change -11.9% -5.81% -8.89%
Cash From Operating Activities -$5.170M -$7.276M -$4.000M
YoY Change -35.13% -22.7% -122.74%
INVESTING ACTIVITIES
Capital Expenditures $40.00K $170.0K $190.0K
YoY Change -71.43% -31.73% -34.48%
Acquisitions
YoY Change
Other Investing Activities -$60.00K -$13.00K $280.0K
YoY Change -300.0% -88.07% 12.0%
Cash From Investing Activities -$100.0K -$371.0K $90.00K
YoY Change -16.67% 13.11% -400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.170M -7.276M -4.000M
Cash From Investing Activities -100.0K -371.0K 90.00K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -5.270M -7.647M -3.910M
YoY Change -58.96% -21.5% -122.27%
FREE CASH FLOW
Cash From Operating Activities -$5.170M -$7.276M -$4.000M
Capital Expenditures $40.00K $170.0K $190.0K
Free Cash Flow -$5.210M -$7.446M -$4.190M
YoY Change -35.76% -22.94% -124.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9868000
CY2019Q1 us-gaap Cost Of Revenue
CostOfRevenue
2045000
CY2018Q1 us-gaap Cost Of Revenue
CostOfRevenue
2924000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11701000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7286000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30363000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37808000
CY2019Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8565000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4729000
CY2019Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1706000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1877000
CY2019Q1 us-gaap Inventory Net
InventoryNet
6707000
CY2018Q4 us-gaap Inventory Net
InventoryNet
8569000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
47341000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
52983000
CY2019Q1 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1801000
CY2018Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1758000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6058000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6390000
CY2019Q1 us-gaap Assets
Assets
61044000
CY2018Q4 us-gaap Assets
Assets
61131000
CY2019Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
5870000
CY2018Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
5211000
CY2019Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
10480000
CY2018Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
10274000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25353000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
27036000
CY2019Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
48670000
CY2018Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
47966000
CY2019Q1 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2426000
CY2018Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2374000
CY2019Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5290000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5292000
CY2019Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
93863000
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
88659000
CY2019Q1 us-gaap Liabilities
Liabilities
120899000
CY2018Q4 us-gaap Liabilities
Liabilities
114012000
CY2019Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
32979000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
33027000
CY2019Q1 plx Grants And Reimbursements Received Or Receivable
GrantsAndReimbursementsReceivedOrReceivable
3000
CY2018Q1 plx Grants And Reimbursements Received Or Receivable
GrantsAndReimbursementsReceivedOrReceivable
843000
CY2019Q1 plx Research Development And Engineering Expense Net
ResearchDevelopmentAndEngineeringExpenseNet
11698000
CY2018Q1 plx Research Development And Engineering Expense Net
ResearchDevelopmentAndEngineeringExpenseNet
6443000
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2230000
CY2018Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2498000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5534000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5151000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7264000
CY2019Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1920000
CY2018Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2220000
CY2019Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
190000
CY2018Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
132000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1730000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2088000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7264000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-7239000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
46000
CY2018Q1 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares
ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
-29898
CY2018Q1 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
16000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
290000
CY2018Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1192000
CY2018Q1 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
1811260
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9844000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37808000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51163000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30363000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41319000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-487000
CY2018Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
18000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-371000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-328000
CY2019Q1 plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
128000
CY2018Q1 plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
342000
CY2018Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
987000
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
145000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
73800491
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
78202020
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3047000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-7239000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
290000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
62000
CY2019Q1 us-gaap Depreciation
Depreciation
405000
CY2018Q1 us-gaap Depreciation
Depreciation
430000
CY2019Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-20000
CY2018Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-28000
CY2019Q1 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
-24000
CY2018Q1 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
-124000
CY2018Q1 plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
44000
CY2018Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-218000
CY2019Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
704000
CY2018Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
619000
CY2018Q1 plx Issuance Of Shares For Interest Payment Regarding Conversion Of Convertible Notes
IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes
205000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3608000
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3512000
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1862000
CY2018Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-814000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
864000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1009000
CY2018Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
121000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7276000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9413000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
170000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
249000
CY2019Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
214000
CY2018Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
188000
CY2019Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-13000
CY2018Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-109000
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
202000
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-103000
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7445000
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3792000
CY2019Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
45000
CY2019Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3615000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4777000
CY2019Q1 us-gaap Inventory Net
InventoryNet
6707000
CY2018Q4 us-gaap Inventory Net
InventoryNet
8569000
CY2019Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9429000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-59855000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-52881000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
148382299000
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
145305982000
CY2017Q4 us-gaap Shares Outstanding
SharesOutstanding
143728797
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-29457000
CY2018Q1 us-gaap Shares Outstanding
SharesOutstanding
145569955
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-35442000
CY2018Q4 us-gaap Shares Outstanding
SharesOutstanding
148382299
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-52881000
CY2019Q1 us-gaap Shares Outstanding
SharesOutstanding
148382299
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-59855000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-7239000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7264000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2019Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2000
CY2018 us-gaap Inventory Write Down
InventoryWriteDown
1100000
CY2019Q1 us-gaap Inventory Write Down
InventoryWriteDown
65000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5844000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1257000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4498000
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
292000
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
328000
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
52000
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1258
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
947000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1135000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
888000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
774000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
770000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6380000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10894000
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5139000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5755000
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y10M2D
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61044000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61131000
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
6422000
CY2018Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
2179000
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
Protalix BioTherapeutics, Inc.
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001006281
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019Q1 dei Trading Symbol
TradingSymbol
PLX
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
148382299
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
36000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5900000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5700000
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
42895000
CY2017Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
25015000
CY2019Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-6909000
CY2018Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-2161000
CY2019Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
42408000
CY2018Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
25033000
CY2019Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
64581000
CY2018Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
91033000

Files In Submission

Name View Source Status
0001144204-19-023895-index-headers.html Edgar Link pending
0001144204-19-023895-index.html Edgar Link pending
0001144204-19-023895.txt Edgar Link pending
0001144204-19-023895-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
plx-20190331.xml Edgar Link completed
plx-20190331.xsd Edgar Link pending
plx-20190331_cal.xml Edgar Link unprocessable
plx-20190331_def.xml Edgar Link unprocessable
plx-20190331_lab.xml Edgar Link unprocessable
plx-20190331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv519981_10q.htm Edgar Link pending
tv519981_ex31-1.htm Edgar Link pending
tv519981_ex31-2.htm Edgar Link pending
tv519981_ex32-1.htm Edgar Link pending
tv519981_ex32-2.htm Edgar Link pending